BioVentus delays $150m IPO



Orthobiologics maker Bioventus postponed its initial public offering which was slated to raise up to $150 million for the company, according to Renaissance Capital.

The company plans to float 8.8 million shares at a price range of between $16 and $18, and plans to list on the NASDAQ Global Market under the ticker “BIOV”.

The initial public offering was scheduled to open today, according to Renaissance Capital, and the company has yet to announce a new date.

At the midpoint of its proposed range, the company would command a fully diluted market value of $566 million, and proceeds from the round should generate between $141 and $159 million, according to an SEC filing from the company.





Print Friendly, PDF & Email

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button